- 現金殖利率: 1.68%、總殖利率: 1.68%、5年平均現金配發率: 130.96%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | 0.90 | -57.55 | 1.50 | -25.0 | 0.00 | 0 | 166.67 | 76.67 | 0.00 | 0 | 166.67 | 76.67 |
| 2022 (9) | 2.12 | 60.61 | 2.00 | 33.33 | 0.00 | 0 | 94.34 | -16.98 | 0.00 | 0 | 94.34 | -16.98 |
| 2021 (8) | 1.32 | 266.67 | 1.50 | 114.29 | 0.00 | 0 | 113.64 | -41.56 | 0.00 | 0 | 113.64 | -41.56 |
| 2020 (7) | 0.36 | -82.86 | 0.70 | -61.11 | 0.00 | 0 | 194.44 | 126.85 | 0.00 | 0 | 194.44 | 126.85 |
| 2019 (6) | 2.10 | 0.96 | 1.80 | 0.0 | 0.00 | 0 | 85.71 | -0.95 | 0.00 | 0 | 85.71 | -0.95 |
| 2018 (5) | 2.08 | 56.39 | 1.80 | 20.0 | 0.00 | 0 | 86.54 | -23.27 | 0.00 | 0 | 86.54 | -23.27 |
| 2017 (4) | 1.33 | -8.28 | 1.50 | 66.67 | 0.00 | 0 | 112.78 | 81.7 | 0.00 | 0 | 112.78 | -13.93 |
| 2016 (3) | 1.45 | 11.54 | 0.90 | 12.5 | 1.00 | 0.0 | 62.07 | 0.86 | 68.97 | -10.34 | 131.03 | -5.36 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 24Q3 (20) | 0.32 | 39.13 | 255.56 | 0.40 | 81.82 | 90.48 | 1.07 | 42.67 | 91.07 |
| 24Q2 (19) | 0.23 | -54.9 | 15.0 | 0.22 | -29.03 | -26.67 | 0.75 | 47.06 | 59.57 |
| 24Q1 (18) | 0.51 | 45.71 | 96.15 | 0.31 | -29.55 | 272.22 | 0.51 | -43.33 | 96.15 |
| 23Q4 (17) | 0.35 | 288.89 | 131.25 | 0.44 | 109.52 | 100.0 | 0.90 | 60.71 | -57.75 |
| 23Q3 (16) | 0.09 | -55.0 | -90.11 | 0.21 | -30.0 | -72.37 | 0.56 | 19.15 | -82.77 |
| 23Q2 (15) | 0.20 | -23.08 | -89.36 | 0.30 | 266.67 | -83.33 | 0.47 | 80.77 | -79.91 |
| 23Q1 (14) | 0.26 | 123.21 | -43.48 | -0.18 | -181.82 | -175.0 | 0.26 | -87.79 | -43.48 |
| 22Q4 (13) | -1.12 | -223.08 | -1766.67 | 0.22 | -71.05 | 257.14 | 2.13 | -34.46 | 61.36 |
| 22Q3 (12) | 0.91 | -51.6 | 18.18 | 0.76 | -57.78 | 33.33 | 3.25 | 38.89 | 128.87 |
| 22Q2 (11) | 1.88 | 308.7 | 93.81 | 1.80 | 650.0 | 133.77 | 2.34 | 408.7 | 260.0 |
| 22Q1 (10) | 0.46 | 866.67 | 243.75 | 0.24 | 271.43 | 209.09 | 0.46 | -65.15 | 243.75 |
| 21Q4 (9) | -0.06 | -107.79 | -112.24 | -0.14 | -124.56 | -131.11 | 1.32 | -7.04 | 266.67 |
| 21Q3 (8) | 0.77 | -20.62 | 2025.0 | 0.57 | -25.97 | 470.0 | 1.42 | 118.46 | 1192.31 |
| 21Q2 (7) | 0.97 | 403.12 | 1070.0 | 0.77 | 450.0 | 1383.33 | 0.65 | 303.12 | 822.22 |
| 21Q1 (6) | -0.32 | -165.31 | -3300.0 | -0.22 | -148.89 | 0 | -0.32 | -188.89 | -3300.0 |
| 20Q4 (5) | 0.49 | 1325.0 | -33.78 | 0.45 | 350.0 | -32.84 | 0.36 | 376.92 | -82.86 |
| 20Q3 (4) | -0.04 | 60.0 | 0.0 | 0.10 | 266.67 | 0.0 | -0.13 | -44.44 | 0.0 |
| 20Q2 (3) | -0.10 | -1100.0 | 0.0 | -0.06 | 0 | 0.0 | -0.09 | -1000.0 | 0.0 |
| 20Q1 (2) | 0.01 | -98.65 | 0.0 | 0.00 | -100.0 | 0.0 | 0.01 | -99.52 | 0.0 |
| 19Q4 (1) | 0.74 | 0.0 | 0.0 | 0.67 | 0.0 | 0.0 | 2.10 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/10 | 1.3 | -0.44 | -7.62 | 16.37 | 9.57 | 5.02 | N/A | - | ||
| 2024/9 | 1.31 | -45.5 | 13.22 | 15.07 | 11.37 | 5.24 | 1.03 | - | ||
| 2024/8 | 2.4 | 57.87 | -1.5 | 13.76 | 11.19 | 5.18 | 1.04 | - | ||
| 2024/7 | 1.52 | 21.11 | 32.48 | 11.36 | 14.32 | 5.12 | 1.05 | - | ||
| 2024/6 | 1.26 | -46.31 | -0.06 | 9.84 | 11.94 | 4.84 | 1.1 | - | ||
| 2024/5 | 2.34 | 88.44 | 3.9 | 8.58 | 13.95 | 4.81 | 1.11 | - | ||
| 2024/4 | 1.24 | 1.65 | 4.44 | 6.24 | 18.24 | 4.74 | 1.12 | - | ||
| 2024/3 | 1.22 | -46.39 | 1.52 | 4.99 | 22.26 | 4.99 | 1.08 | - | ||
| 2024/2 | 2.28 | 52.77 | 15.08 | 3.77 | 30.93 | 5.15 | 1.05 | - | ||
| 2024/1 | 1.49 | 8.51 | 65.8 | 1.49 | 65.8 | 5.37 | 1.0 | 主要係去年1月春節假期9天,實際工作天少;另逢1月流感季節，客戶對本公司產品需求大增，致合併營收較去年同期增加。 | ||
| 2023/12 | 1.38 | -44.97 | 5.44 | 18.82 | -21.54 | 5.29 | 1.02 | - | ||
| 2023/11 | 2.5 | 77.09 | 10.79 | 17.44 | -23.09 | 5.07 | 1.06 | - | ||
| 2023/10 | 1.41 | 22.03 | 26.39 | 14.94 | -26.84 | 5.01 | 1.07 | - | ||
| 2023/9 | 1.16 | -52.6 | -26.23 | 13.53 | -29.91 | 4.75 | 1.24 | - | ||
| 2023/8 | 2.44 | 112.36 | -29.36 | 12.38 | -30.24 | 4.85 | 1.22 | - | ||
| 2023/7 | 1.15 | -8.64 | -27.86 | 9.94 | -30.45 | 4.66 | 1.26 | - | ||
| 2023/6 | 1.26 | -44.18 | -48.17 | 8.79 | -30.78 | 4.7 | 1.21 | - | ||
| 2023/5 | 2.25 | 89.42 | -41.99 | 7.53 | -26.67 | 4.65 | 1.22 | - | ||
| 2023/4 | 1.19 | -1.18 | -35.22 | 5.27 | -17.34 | 4.37 | 1.3 | - | ||
| 2023/3 | 1.2 | -39.23 | -14.13 | 4.09 | -10.12 | 4.09 | 1.44 | - | ||
| 2023/2 | 1.98 | 120.1 | 1.76 | 2.88 | -8.33 | 4.19 | 1.41 | - | ||
| 2023/1 | 0.9 | -30.98 | -24.77 | 0.9 | -24.77 | 4.46 | 1.32 | - | ||
| 2022/12 | 1.3 | -42.18 | -6.56 | 23.99 | 26.16 | 4.68 | 1.17 | - | ||
| 2022/11 | 2.26 | 102.02 | 7.44 | 22.68 | 28.75 | 4.94 | 1.11 | - | ||
| 2022/10 | 1.12 | -28.77 | -2.88 | 20.43 | 31.64 | 6.14 | 0.89 | - | ||
| 2022/9 | 1.57 | -54.61 | 11.33 | 19.31 | 34.4 | 6.62 | 0.81 | - | ||
| 2022/8 | 3.45 | 116.88 | 58.77 | 17.74 | 36.91 | 7.47 | 0.71 | 主係檢驗試劑部門和其他部門之產品，市場需求增加，致整體營收增加。 | ||
| 2022/7 | 1.59 | -34.36 | -6.81 | 14.29 | 32.5 | 7.9 | 0.68 | - | ||
| 2022/6 | 2.43 | -37.52 | 35.11 | 12.69 | 39.91 | 8.15 | 0.68 | - | ||
| 2022/5 | 3.88 | 111.51 | 52.78 | 10.27 | 41.09 | 7.12 | 0.78 | 主係檢驗試劑部門和其他部門之產品，市場需求增加，致整體營收增加。 | ||
| 2022/4 | 1.84 | 30.98 | 84.86 | 6.38 | 34.81 | 5.19 | 1.08 | 主係檢驗試劑部門和其他部門之產品，市場需求增加，致整體營收增加。 | ||
| 2022/3 | 1.4 | -27.98 | 26.68 | 4.55 | 21.52 | 4.55 | 1.19 | - | ||
| 2022/2 | 1.95 | 62.69 | 15.26 | 3.14 | 19.35 | 4.54 | 1.19 | - | ||
| 2022/1 | 1.2 | -14.27 | 26.67 | 1.2 | 26.67 | 4.69 | 1.16 | - | ||
| 2021/12 | 1.4 | -33.52 | -18.89 | 19.01 | 21.2 | 4.65 | 1.14 | - | ||
| 2021/11 | 2.1 | 82.6 | -1.85 | 17.62 | 26.14 | 4.66 | 1.14 | - | ||
| 2021/10 | 1.15 | -18.34 | -0.1 | 15.52 | 31.2 | 4.73 | 1.12 | - | ||
| 2021/9 | 1.41 | -35.27 | 9.04 | 14.37 | 34.58 | 5.29 | 1.08 | - | ||
| 2021/8 | 2.18 | 27.29 | 31.07 | 12.96 | 38.1 | 5.68 | 1.01 | - | ||
| 2021/7 | 1.71 | -4.83 | 66.01 | 10.78 | 39.61 | 6.05 | 0.94 | 主係新冠肺炎疫情，檢驗試劑及感控部門之產品，市場需求增加，及新併入之子公司營收，致整體營收增加。 | ||
| 2021/6 | 1.8 | -29.34 | 125.5 | 9.07 | 35.54 | 5.33 | 1.09 | 主係新冠肺炎疫情，檢驗試劑及感控部門之產品，市場需求增加，致整體營收增加。 | ||
| 2021/5 | 2.54 | 155.92 | 67.32 | 7.28 | 23.39 | 4.64 | 1.25 | 主係新冠肺炎疫情，檢驗試劑及感控部門之產品，市場需求增加，致整體營收增加。 | ||
| 2021/4 | 0.99 | -10.24 | 2.3 | 4.73 | 8.15 | 3.79 | 1.53 | - | ||
| 2021/3 | 1.11 | -34.46 | 14.17 | 3.74 | 9.81 | 3.74 | 1.57 | - | ||
| 2021/2 | 1.69 | 78.79 | 3.2 | 2.63 | 8.08 | 4.35 | 1.35 | - | ||
| 2021/1 | 0.94 | -45.11 | 18.07 | 0.94 | 18.07 | 4.81 | 1.23 | - | ||
| 2020/12 | 1.72 | -19.55 | 6.61 | 15.69 | -0.33 | 5.01 | 1.12 | - | ||
| 2020/11 | 2.14 | 85.85 | 8.69 | 13.97 | -1.13 | 4.58 | 1.22 | - | ||
| 2020/10 | 1.15 | -10.87 | 7.98 | 11.83 | -2.72 | 4.1 | 1.37 | - | ||
| 2020/9 | 1.29 | -22.19 | 25.46 | 10.67 | -3.75 | 3.98 | 1.1 | - | ||
| 2020/8 | 1.66 | 61.22 | 1.11 | 9.38 | -6.74 | 3.49 | 1.26 | - | ||
| 2020/7 | 1.03 | 29.26 | 23.06 | 7.72 | -8.27 | 3.35 | 1.31 | - | ||
| 2020/6 | 0.8 | -47.57 | -14.87 | 6.69 | -11.73 | 3.29 | 1.22 | - | ||
| 2020/5 | 1.52 | 56.47 | -8.82 | 5.9 | -11.28 | 3.46 | 1.16 | - | ||
| 2020/4 | 0.97 | 0.17 | -30.94 | 4.38 | -12.11 | 3.58 | 1.12 | - | ||
| 2020/3 | 0.97 | -40.76 | -9.42 | 3.41 | -4.7 | 3.41 | 1.08 | - | ||
| 2020/2 | 1.64 | 104.56 | 14.17 | 2.44 | -2.68 | 4.05 | 0.91 | - | ||
| 2020/1 | 0.8 | -50.44 | -25.27 | 0.8 | -25.27 | 4.38 | 0.84 | - | ||
| 2019/12 | 1.61 | -17.98 | 24.36 | 15.74 | 11.81 | 0.0 | N/A | - | ||
| 2019/11 | 1.97 | 84.63 | 8.49 | 14.13 | 10.53 | 0.0 | N/A | - |
